Atai Beckley Inc Stock Price, News & Analysis

atai Life Sciences reported positive progress in its therapeutic programs, including encouraging topline results from COMP360’s Phase 2b study for treatment-resistant depression. With cash and equivalents totaling $430.3 million as of September 30, 2021, the company shows strong financial backing after its IPO. Upcoming milestones include Phase 2a data for RL-007 in cognitive impairment expected by the end of Q4 2021. The company's focus on mental health, combined with the recent launch of the atai Impact philanthropic program, positions it for potential growth.

atai Life Sciences N.V. (Nasdaq: ATAI) will host a conference call on November 15, 2021, at 8:30 a.m. ET to discuss its Q3 2021 financial results and provide a business update. Attendees can access the call via dial-in numbers and a dedicated conference ID. Founded in 2018, atai focuses on developing innovative treatments for mental health disorders, including depression and anxiety. The company leverages funding, technology, and regulatory expertise to advance psychedelic therapies and improve treatment options in mental healthcare.

atai Life Sciences N.V. (Nasdaq: ATAI) announced its participation in key investor conferences in November 2021 aimed at transforming mental health treatment. Notable events include the Berenberg US CEO Conference on November 9-10, and the Credit Suisse 30th Annual Healthcare Conference on November 11 at 9:40 a.m. ET, featuring a fireside chat format. The 12th Annual Jefferies London Healthcare Conference is set for November 18, also featuring a fireside chat at 8:00 a.m. ET. Archived webcasts will be available on the company's website.

atai Life Sciences announced promising interim data from its Phase 2a trial of RL-007, which targets Cognitive Impairment Associated with Schizophrenia (CIAS). The results from the initial 8-patient cohort indicate potential cognitive benefits, leading the company to accelerate its development timeline. The trial showcased positive changes in two biomarkers, suggesting improved cognition. The full results are anticipated by year-end 2021. The financial support will expedite planning for the next clinical trial before completing the current one.

atai Life Sciences (Nasdaq: ATAI) has announced the formation of PsyProtix, a new platform focused on precision psychiatry for treatment-resistant depression (TRD) and other mental health conditions. This collaboration with Duke University aims to develop therapeutics that account for patient variability in genes and lifestyle instead of a traditional trial-and-error approach. Over 300 million individuals suffer from major depressive disorder, with TRD presenting significantly higher medical costs. PsyProtix seeks to customize treatments based on metabolomic mechanisms to improve therapeutic outcomes.

DemeRx IB, a platform company of atai Life Sciences (Nasdaq: ATAI), has initiated a Phase 1/2a clinical trial of ibogaine HCl (DMX-1002) for opioid use disorder. The trial has begun dosing with recreational drug users and healthy volunteers in the UK, focusing on safety, tolerability, pharmacokinetics, and efficacy. Previous studies indicate ibogaine's potential for rapid and sustained efficacy in treating opioid dependence. Safety data is expected by early 2022. The trial aims to contribute to existing literature on ibogaine as a treatment option amidst the ongoing opioid crisis.

atai Life Sciences (Nasdaq: ATAI) has amended its loan agreement with IntelGenx Technologies Corp., increasing its loan commitment from US$2.5 million to US$8.5 million to support IntelGenx' graduation to the Toronto Stock Exchange. The additional US$6 million will be allocated in two phases of US$3 million each in January 2022 and January 2023. This move is based on promising early data from ongoing studies. The loan, which matures in January 2024, bears an 8% interest rate, while IntelGenx focuses on developing innovative treatments for mental health disorders.

Perception Neuroscience, a subsidiary of atai, has initiated a Phase 2a clinical study to assess the safety and efficacy of PCN-101 (R-ketamine) for Treatment Resistant Depression (TRD). The trial will enroll 93 patients across 3 arms, with doses of either placebo, 30 mg, or 60 mg of R-ketamine. Patients will be monitored for depressive symptoms over 14 days, with topline data expected by the end of 2022. The study aims to provide insight into R-ketamine's potential as a rapidly-acting antidepressant, addressing the needs of nearly 100 million people affected by TRD.

atai Life Sciences (Nasdaq: ATAI) announces a usability study of its Introspect Digital Therapeutics app, aimed at enhancing ketamine therapy for treatment-resistant depression (TRD), affecting 100 million globally. Conducted in collaboration with Kadima Neuropsychiatry, the study will assess user acceptability, therapeutic content introduction, and treatment settings across three cohorts. Atai believes this digital integration could improve access to mental health care, aligning with its mission to innovate psychiatric treatments and address the substantial unmet need in mental health.